Published in Pharmacopsychiatry on March 01, 1999
The pharmacology of sigma-1 receptors. Pharmacol Ther (2009) 3.12
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets (2011) 1.22
The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders. Cell Mol Neurobiol (2007) 0.87
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl) (2009) 0.86
No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies. BMC Psychiatry (2003) 0.77
Biphasic development of carrageenin edema in rats. J Pharmacol Exp Ther (1969) 4.24
Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study. Eur Arch Psychiatry Clin Neurosci (1992) 2.68
Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology (2000) 2.36
Molecular characterization and functional analysis of the leukocyte surface protein CD31. J Immunol (1990) 2.07
Low lumbar bone mineral density in patients with major depression. Am J Psychiatry (1994) 2.05
Toxic hepatitis by clozapine treatment. Am J Psychiatry (1993) 1.83
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
Diurnal variations in the human host response to endotoxin. J Infect Dis (1996) 1.71
Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry (1995) 1.49
Solventogenic enzymes of Clostridium acetobutylicum: catalytic properties, genetic organization, and transcriptional regulation. FEMS Microbiol Rev (1995) 1.45
Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab (1997) 1.44
Patterns of response to repeated total sleep deprivations in depression. J Affect Disord (2001) 1.44
Major bleeding complications after cardiopulmonary resuscitation: impact of thrombolytic treatment. J Intern Med (2003) 1.42
Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology (1995) 1.38
Quantification of regional intrapulmonary oxygen partial pressure evolution during apnea by (3)He MRI. J Magn Reson (1999) 1.34
Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT--initial experience. Radiology (1999) 1.32
With aging in humans the activity of the hypothalamus-pituitary-adrenal system increases and its diurnal amplitude flattens. Life Sci (1997) 1.22
The limited utility of the dexamethasone suppression test for the diagnostic process in psychiatry. Br J Psychiatry (1984) 1.19
Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab (1999) 1.16
Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J (1999) 1.16
Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology (1998) 1.12
Relationship between clinical pain complaints and pain sensitivity in patients with depression and panic disorder. Psychosom Med (2000) 1.11
Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry (1996) 1.10
Pain perception in psychiatric disorders: a review of the literature. J Psychiatr Res (1994) 1.08
Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry (2008) 1.07
gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem (1995) 1.04
Nocturnal sleep in Huntington's disease. J Neurol (1991) 1.03
(3)he-MRI-based measurements of intrapulmonary p(O2) and its time course during apnea in healthy volunteers: first results, reproducibility, and technical limitations. NMR Biomed (2000) 1.03
Phenotype of human T cells expressing CD31, a molecule of the immunoglobulin supergene family. Immunology (1992) 1.01
Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol Aging (1995) 0.99
Blood glucose concentration after cardiopulmonary resuscitation influences functional neurological recovery in human cardiac arrest survivors. J Cereb Blood Flow Metab (1997) 0.99
Consequences of deterministic and random dynamics for the course of affective disorders. Biol Psychiatry (1999) 0.99
Sleep in schizophrenia: a polysomnographic study on drug-naive patients. Neuropsychopharmacology (1997) 0.98
Cirrhosis and diabetes. II. Association of impaired glucose tolerance with portal-systemic shunting in Laennec's cirrhosis. Am J Dig Dis (1971) 0.98
The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. J Intern Med (2000) 0.98
Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. J Neurol (2005) 0.96
Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry (1995) 0.96
Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci (1992) 0.96
Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry (1998) 0.95
Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology (1997) 0.95
Pain perception in depression: relationships to symptomatology and naloxone-sensitive mechanisms. Psychosom Med (1994) 0.93
Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom Med (1999) 0.93
Nocturnal sleep EEG in patients with HIV infection. Eur Arch Psychiatry Clin Neurosci (1991) 0.92
Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress Anxiety (1998) 0.92
Pain sensitivity in anorexia nervosa and bulimia nervosa. Biol Psychiatry (1991) 0.91
White blood cells and cortisol after sleep deprivation and recovery sleep in humans. Eur Arch Psychiatry Clin Neurosci (2000) 0.91
Paired inspiratory/expiratory spiral CT and continuous respiration cine CT in the diagnosis of tracheal instability. Eur Radiol (2001) 0.91
Tracheal rupture after emergency intubation during cardiopulmonary resuscitation. Resuscitation (1995) 0.91
Vienna Transdanube Aging "VITA": study design, recruitment strategies and level of participation. J Neural Transm Suppl (2002) 0.90
Effects of antipsychotics and vitamin C on the formation of reactive oxygen species. J Psychopharmacol (2009) 0.90
Satiety and cholecystokinin. Int J Eat Disord (1994) 0.90
Vocal cord paralysis: a toxic reaction to vinblastine (NSC-49842) therapy. Cancer Chemother Rep (1971) 0.90
Estrogen hormones reduce lipid peroxidation in cells and tissues of the central nervous system. J Neurochem (1999) 0.89
Cirrhosis and diabetes. I. Increased incidence of diabetes in patients with Laennec's cirrhosis. Am J Dig Dis (1969) 0.89
Depression in Parkinson's disease. An update. Adv Neurol (2001) 0.89
In quest of identifying vulnerability markers for psychiatric disorders by all-night polysomnography. Arch Gen Psychiatry (1995) 0.88
The influence of dieting on the menstrual cycle of healthy young women. J Clin Endocrinol Metab (1985) 0.88
Resting metabolic rate and total energy expenditure in acute and weight recovered patients with anorexia nervosa and in healthy young women. Int J Eat Disord (1994) 0.88
Volumetry of ventilated airspaces by 3He MRI: preliminary results. Invest Radiol (2001) 0.87
Brain morphology and sleep EEG in patients with Huntington's disease. Eur Arch Psychiatry Clin Neurosci (1991) 0.87
Endotoxin-induced changes in sleep and sleepiness during the day. Psychoneuroendocrinology (1998) 0.87
Influence of endotoxin on nocturnal sleep in humans. Am J Physiol (1993) 0.87
Anxiety disorders: similarities and differences of comorbidity in treated and untreated groups. Br J Psychiatry Suppl (1991) 0.86
Alterations of nocturnal sleep in patients with HIV infection. Acta Neurol Scand (1991) 0.85
Dose-dependence of bacterial lipopolysaccharide (LPS) effects on peak response and time course of the immune-endocrine host response in humans. Inflamm Res (1999) 0.85
Enlargement of cerebrospinal fluid spaces in long-term benzodiazepine abusers. Psychol Med (1987) 0.85
Pain perception in patients with eating disorders. Psychosom Med (1991) 0.85
[Hoigne syndrome. Case report and current literature review]. Nervenarzt (2001) 0.85
[Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography]. Radiologe (1997) 0.84
Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro. Neurosci Lett (1999) 0.84
Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood (1996) 0.83
Particle-associated RNA dependent DNA polymerase and high-molecular-weight RNA in a human cell line derived from polycythemia vera bone marrow. J Natl Cancer Inst (1975) 0.83
Adenosine for the management of patients with tachycardias--a new protocol. Eur Heart J (1994) 0.83
Regulation of glucocorticoid receptor-mRNA in human blood cells by amitriptyline and dexamethasone. J Psychiatr Res (1999) 0.83
Pre-morbid psychometric profile of subjects at high familial risk for affective disorder. Psychol Med (1997) 0.83
Influence of endotoxin on daytime sleep in humans. Infect Immun (1996) 0.82
Disturbed cholecystokinin secretion in patients with eating disorders. Life Sci (1991) 0.82
Contrast-enhanced magnetization transfer imaging: improvement of brain tumor conspicuity and delineation for radiosurgical target volume definition. Radiother Oncol (1997) 0.81
Endotoxin enhances EEG alpha and beta power in human sleep. Sleep (1994) 0.81
Chronic meningitis and lacunar stroke in Fabry disease. J Neurol (2007) 0.80
Mitochondrial genotype and risk for Alzheimer's disease: cross-sectional data from the Vienna-Transdanube-Aging "VITA" study. J Neural Transm (Vienna) (2004) 0.80
Macroscopic tumor volume of malignant glioma determined by contrast-enhanced magnetic resonance imaging with and without magnetization transfer contrast. Magn Reson Imaging (1996) 0.79
The Munich vulnerability study on affective disorders: overview of the cross-sectional observations at index investigation. J Psychiatr Res (1999) 0.79
Expression and glucocorticoid regulation of macrophage migration inhibitory factor (MIF) in hippocampal and neocortical rat brain cells in culture. Brain Res (2000) 0.79
Cerebral atrophy and vigilance performance in patients with anorexia nervosa and bulimia nervosa. Neuropsychobiology (1989) 0.79
The effect of neuroendocrine secretion on brain morphology and EEG sleep in patients with eating disorders. Eur Arch Psychiatry Neurol Sci (1989) 0.79
Assessment of somatosensory indicators of polyneuropathy in patients with eating disorders. Eur Arch Psychiatry Clin Neurosci (1991) 0.79